Universität zu Köln

Uta, Rothschild, Laurent, Muller, Axel, Lechner, Hans, Schloessr A., Dirk, Beutner, Heinz, Laubli, Alfred, Zippelius and Sacha, Rothschild, I (2018). Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions. Swiss Med. Wkly., 148. MUTTENZ: E M H SWISS MEDICAL PUBLISHERS LTD. ISSN 1424-3997

Full text not available from this repository.

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a frequent tumour arising from multiple anatomical subsites in the head and neck region. The treatment for early-stage disease is generally single modality, either surgery or radiotherapy. The treatment for locally advanced tumours is multimodal. For recurrent/metastatic HNSCC palliative chemotherapy is standard of care. The prognosis is limited and novel treatment approaches are urgently needed. HNSCC evades immune responses through multiple resistance mechanisms. HNSCC is particularly characterised by an immunosuppressive environment which includes the release of immunosuppressive factors, activation, expansion of immune cells with inhibitory activity and decreased tumour immunogenicity. An in-depth understanding of these mechanisms led to rational design of immunotherapeutic approaches and clinical trials. Currently, only immune checkpoint inhibitors, namely monoclonal antibodies targeting the immune inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have proven clinical efficacy in randomised phase III trials. The PD-1 inhibitor nivolumab is the only drug approved for platinum-refractory recurrent/metastatic HNSCC. However, many more immunotherapeutic treatment options are currently under investigation. Ongoing trials are investigating immunotherapeutic approaches also in the curative setting and combination therapies using different immunotherapeutic approaches. This review article summarises current knowledge of the role of the immune system in the development and progression of HNSCC, and provides a comprehensive overview on the development of immunotherapeutic approaches.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Uta, Rothschild UNSPECIFIED UNSPECIFIED UNSPECIFIED Laurent, Muller UNSPECIFIED UNSPECIFIED UNSPECIFIED Axel, Lechner UNSPECIFIED UNSPECIFIED UNSPECIFIED Hans, Schloessr A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Dirk, Beutner UNSPECIFIED UNSPECIFIED UNSPECIFIED Heinz, Laubli UNSPECIFIED UNSPECIFIED UNSPECIFIED Alfred, Zippelius UNSPECIFIED UNSPECIFIED UNSPECIFIED Sacha, Rothschild, I UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-186613
DOI:	10.4414/smw.2018.14625
Journal or Publication Title:	Swiss Med. Wkly.
Volume:	148
Date:	2018
Publisher:	E M H SWISS MEDICAL PUBLISHERS LTD
Place of Publication:	MUTTENZ
ISSN:	1424-3997
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SQUAMOUS-CELL CARCINOMA; REGULATORY T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; HPV-ASSOCIATED HEAD; HUMAN-PAPILLOMAVIRUS; PERIPHERAL-BLOOD; CERVICAL-CANCER; IMMUNE CELLS; LUNG-CANCER; OPEN-LABEL Multiple languages Medicine, General & Internal Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/18661